ArticleScientific reports2025
Development and evaluation of curcumin nano-niosomes for glioma-targeted therapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Therapeutic potentials of curcumin in prostate cancer: a comprehensive review of pathways and clinical prospects.Prostate international · 2026Review
- Nanotechnology for efficient delivery of TCM active ingredients in treating brain diseases.Materials today. Bio · 2026Review
- Therapeutic profiling of dihydroartemisinin using in vitro and in vivo models reveals anti-glioma potential.Cancer cell international · 2026Article
- A Comprehensive Analysis of Natural Bioactive Molecules for the Treatment and Control of Glioblastoma Multiforme (GBM) Targeting Underlying Molecular Mechanism.Chemistry & biodiversity · 2026Review
- Causal relationships between blood metabolites and glioblastoma risk: a large-scale Mendelian randomization study.Discover oncology · 2025Article
- A Comprehensive Review of Niosomes: Composition, Structure, Formation, Characterization, and Applications in Bioactive Molecule Delivery Systems.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma remains a significant global health challenge, and is characterized by a persistently high mortality rate. Chemotherapy is a common treatment for glioma, but many anticancer drugs exhibit poor permeability across the blood-brain barrier (BBB) and fail to reach tumor tissues adequately, while also exerting toxic effects on normal cells. To address these issues, this study investigated the use of niosomes (Nio), which are biocompatible, biodegradable, and non-immunogenic, to encapsulate curcumin (Cur) and enhance its delivery to glioma tissues. Niosomes were prepared using the non-ionic surfactant sorbitan monostearate (Span 60) and cholesterol as carrier materials, and subsequently modified with transferrin (TF) to facilitate receptor-mediated transport across the BBB. The resulting TF-modified curcumin niosomes (TF-Cur-Nio) demonstrated enhanced targeting of brain tumors, improved anti-glioma efficacy, and favorable in vivo safety. These findings suggest that the TF-Cur-Nio delivery system has significant potential for advancing glioma treatment by overcoming the limitations of conventional chemotherapy and improving drug delivery to the brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.